



CIN NO. L24110MH1989PLC052251  
**UNAUDITED STANDALONE FINANCIAL RESULTS (PROVISIONAL) FOR THE QUARTER  
 ENDED MARCH 31, 2015.**

**BIO-MEDICINE LTD.**  
 ISO 9001 - 2008 Certified Company  
 (Rs. In Lacs)

SR. NO.	PARTICULARS	Quarter Ended			Nine Months Ended		Year Ended 30/06/2014 (Audited)
		31/03/2015	31/12/2014	31/03/2014	31/03/2015	31/03/2014	
1	Net Sales / Income from Operations	12,915.32	23,792.70	31,568.54	69,199.64	96,700.96	131,376.83
	Total Income	12,915.32	23,792.70	31,568.54	69,199.64	96,700.96	131,376.83
2	<b>Total Expenditure</b>						
a)	(Increase)/Decrease in Stock in Trade	(3,290.04)	9,046.42	(1,645.70)	3,906.53	(3,185.50)	(6,221.38)
b)	Consumption of Materials	13,096.46	19,862.86	21,670.36	56,064.01	68,231.60	94,808.62
c)	Purchases of Trading Goods	1,298.52	2,015.61	6,409.11	8,843.17	17,229.55	22,687.57
d)	Employees Cost	681.85	278.03	607.32	1,620.16	1,653.33	2,307.62
e)	Depreciation	769.42	300.39	419.89	1,372.23	1,236.74	1,535.44
f)	Other Expenditure	1,385.56	143.00	605.76	2,720.90	1,494.98	2,088.53
	<b>Total</b>	<b>13,941.77</b>	<b>31,646.31</b>	<b>28,066.74</b>	<b>74,527.00</b>	<b>86,660.70</b>	<b>117,206.40</b>
3	Profit from Operations before Exchange Rate Difference, Other Income, Interest & Exceptional Items (1 - 2)	(1,026.45)	(7,853.61)	3,501.80	(5,327.36)	10,040.26	14,170.43
4	Other Income	21.41	16.26	15.26	143.95	54.88	167.71
5	Profit from Operations before Interest & Exceptional items (3 + 4)	(1,005.04)	(7,837.35)	3,517.06	(5,183.41)	10,095.14	14,338.14
6	Interest	1,330.97	1,661.37	1,401.03	4,389.13	3,895.86	5,313.78
7	Profit after Interest but before Exception items (5-6)	(2,336.01)	(9,498.72)	2,116.03	(9,572.54)	6,199.28	9,024.36
8	Exception Items	(2,548.61)	1,150.94	(141.99)	(3,836.56)	(403.67)	548.98
9	Profit(+)/Loss(-) from Ordinary Activities before tax (7-8)	(4,884.62)	(10,649.66)	1,974.04	(13,411.10)	5,795.61	8,475.38
10	Tax Expenses	-	(312.68)	190.11	-	869.14	1,513.66
11	Net Profit before ordinary activities (9 - 10)	(4,884.62)	(10,336.98)	1,783.93	(13,411.10)	4,926.47	6,961.72
12	Extra Ordinary Items (Net of Tax)	-	-	-	-	-	-
13	Net Profit after Taxes (11 - 12)	(4,884.62)	(10,336.98)	1,783.93	(13,411.10)	4,926.47	6,961.72
14	Paid up Equity Share Capital (Face value of Rs.2/- each)	2,245.69	2,111.38	2,111.38	2,245.69	2,111.38	2,111.38
15	Reserves excluding Revaluation Reserves	-	-	-	-	-	33,327.04
16	<b>Earning Per Shares (Before Extra Ordinary Item)</b>						
i)	Basic (Not Annualised)	(4.35)	(9.79)	1.69	(11.94)	4.67	6.59
ii)	Diluted E. P. S (Not Annualised)	(3.00)	(6.71)	1.69	(8.24)	4.67	4.65
17	<b>Earning Per Shares (After Extra Ordinary Items)</b>						
i)	Basic (Not Annualised)	(4.35)	(9.79)	1.69	(11.94)	4.67	6.59
ii)	Diluted E. P. S (Not Annualised)	(3.00)	(6.71)	1.69	(8.24)	4.67	4.65

**Part -II**

SR. NO.	PARTICULARS	Quarter Ended			Nine Months Ended		Year Ended 30/06/2014 (Audited)
		31/03/2015	31/12/2014	31/03/2014	31/03/2015	31/03/2014	
(A)	Aggregate of Public Shareholdings						
	No. of Shares	43,017,020	43,017,020	42,017,020	43,017,020	42,017,020	42,017,020
	Percentage of Shareholdings	38.31%	40.75%	39.80%	38.31%	39.80%	39.80%
17	Promoters & promoter group Shareholding						
a)	<b>Pledged / Encumbered</b>						
	- Number of Shares	4,000,000	4,000,000	NIL	4,000,000	NIL	5,000,000
	- Percentage of Shares	5.77%	6.39%	NIL	5.77%	NIL	7.87%
	(as a % of the total shareholding of promoter & promoter group)						
	- Percentage of Shares	3.56%	3.79%	NIL	3.56%	NIL	4.74%
	(as a % of the total share capital of the Company)						
b)	<b>Non-encumbered</b>						
	- Number of Shares	65,267,380	58,551,980	63,551,980	65,267,380	63,551,980	58,551,980
	- Percentage of Shares	94.23%	93.61%	100.00%	94.23%	100.00%	92.13%
	(as a % of the total shareholding of promoter & promoter group)						
	- Percentage of Shares	61.69%	59.25%	60.20%	58.13%	60.20%	60.20%
	(as a % of the total share capital of the Company)						

PARTICULARS	3 Months Ended on 31/03/2015
(B) <b>INVESTORS COMPLAINTS</b>	
Opening Balance in Complaints	NIL
Received during the Quarter	10
Disposed off during the Quarter	10
Closing Balance	NIL

**NOTES:**

1) The above results for the quarter ended March 31, 2015 have been reviewed by the Audit Committee and were taken on record by the Board of Directors in its meeting on May 14, 2015.  
 2) The Company has completed the formalities of Restructuring of its debts.

3) In Exception items company has provided FCCB interest, loss in foreign exchange and written off of sales.  
 4) The "Limited Review" required under Clause 41 of the Listing Agreement has been done by the Statutory auditors of the Comp  
 5) Previous years figures have been regrouped and recast wherever necessary

Place : Mumbai.  
 Date : 14.05.2015

For Sharon Bio-Medicine Ltd

*Savita*  
 Savita Gowda  
 Managing Director

Regd. Off. & Works I : W-34 & 34/1, MIDC, Talaja, Dist-Raigad, Maharashtra (India),

Works II: Plot No. L-6, MIDC, Talaja, Dist-Raigad, Maharashtra (India)

Admin Office : 312, C Wing, BSEL Tech Park, Sector - 30(A), Vashi, Navi Mumbai - 400 705

Tel.: 91 22 - 67944000, Fax : 91 22 - 67944001

Head Office : Plot No. 163, Smt Janakidevi Public School Rd., SVP Nagar, Andheri (West), Mumbai - 400 053.

Tel. :91 22 26323192 / 93 / 94 Fax : 26323140 E-mail : info@sharonbio.com

www.sharonbio.com

*Caring for relationships*

CIN NO. L24110MH1989PLC052251

*CA. S. C. Agrawal*

B. Com., (Hons.) LL.B., F.C.A., DISA (ICAI)



**Shyam C. Agrawal & Co.**

**Chartered Accountants**

14, Nityanand Nagar No. 2,  
Opp. Bank of Maharashtra,  
Near Sanjeevani Hospital, Sahar Road,  
Andheri (E), Mumbai - 400 069.  
Tel. : (O) 2684 0916 • Tele Fax : 2683 5699  
E-mail : shyam31774@yahoo.com  
Mobile : 98200-52168

**REVIEW REPORT**

We have reviewed the accompanying statement of Unaudited financial results of M/s. Sharon Bio-Medicine Ltd., for the quarter ended on 31<sup>st</sup> March, 2015 except for the disclosures regarding 'Public Shareholding' and 'Promoter and Promoter Group Shareholding' which have been traced from disclosures made by the management and have not been audited by us. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors/Committee of Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2400, engagements to Review Financial Statements issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review misstatement. A review is limited primarily to inquires of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of audited financial results prepared in accordance with applicable accounting standards notified pursuant to the Companies Act (Accounting Standards) Rules, 2006 as per section 211 (3C) of the Companies Act, 1956 and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Clause 41 of the Listing Agreement including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Shyam C. Agrawal & Co.  
Chartered Accountants

14/5/2015  
Shyam Agrawal  
Proprietor

